X0609 4 2026-08-14 0001623526 Stoke Therapeutics, Inc. STOK 0001522780 Kaye Edward M. MD false C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE BEDFORD MA 01730 true false false false 0 Common Stock 2026-08-14 4 M 0 26250 0 A 137124 D Common Stock 2026-08-18 4 S 0 11930 32.0072 D 125194 D Common Stock 2026-08-18 4 S 0 637 32.4681 D 124557 D Performance Stock Units 2026-08-14 4 M 0 26250 0 D 2026-08-14 Common Stock 26250 0 D The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive. Each performance stock unit represents a right to receive one share of the Issuer's common stock. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. /s/ Jonathan Allan, Attorney-in-Fact 2026-08-18